Xia Han
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, Acute Lymphoblastic Leukemia research, Cancer Genomics and Diagnostics
Most-Cited Works
- → Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts(2005)832 cited
- → Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection(2007)343 cited
- → The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors(2008)163 cited
- → Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity(2004)135 cited
- → Overweight, Gestational Weight Gain and Elevated Fasting Plasma Glucose and Their Association with Macrosomia in Chinese Pregnant Women(2013)33 cited
- → Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel(2018)15 cited
- [Expression of autophagy related gene Beclin1 and MAPLC3 in bone marrow mononuclear cells isolated from acute leukemia patients and its significance].(2011)
- → Abstract CT077: Potential utility of minimal residual disease (MRD) to identify relapse in pediatric and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients treated with tisagenlecleucel(2019)4 cited
- [Expression characteristics of SDF-1 receptor CXCR4 in mesenchymal stem cells derived from human umbilical cord tissue].(2011)
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy iN Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial(2020)